Multimodality treatment of intrahepatic cholangiocarcinoma: A review

J Surg Oncol. 2016 Jan;113(1):62-83. doi: 10.1002/jso.24093.

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary hepatic cancer in the United States. Currently, curative treatment involves aggressive surgery. Chemotherapy and radiation treatments have been used for unresectable tumors with some success. Optimizing the use of current and developing novel multimodality treatment for iCCA is essential to improving outcomes.

Keywords: intrahepatic cholangiocarcinoma; multimodality.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bile Duct Neoplasms / epidemiology
  • Bile Duct Neoplasms / therapy*
  • Catheter Ablation
  • Cholangiocarcinoma / epidemiology
  • Cholangiocarcinoma / therapy*
  • Combined Modality Therapy / methods*
  • Embolization, Therapeutic / methods
  • Humans
  • Immunotherapy / methods
  • Prognosis
  • Proton Therapy
  • Radiosurgery
  • United States / epidemiology
  • Yttrium Radioisotopes / therapeutic use

Substances

  • Yttrium Radioisotopes